Abstract
As STAT3 has been validated as an anticancer target, its inhibitors have been shown to possess therapeutic promise for the treatment of human cancers. To identify novel and selective STAT3 inhibitors, a virtual screening based on the STAT3 SH2 domain was performed and a small molecule, 2-phenylquinoline-4-carboxylic acid (5a), with an inhibition constant Ki value of 17.53 μM to STAT3 was discovered. On this basis, the derivatives of 5a including esters, amides and dimers were synthesized. The bioactivity and inhibitory selectivity of the derivatives were assayed using human breast cancer cell lines, MDA-MB-468 and MCF-7. Among the derivatives, 5c and 9b showed the most potent inhibitory activity with a good selectivity, and also inhibited STAT3 protein level of MDA-MB-468 cells. The results demonstrated a successful application of virtual screening for lead discovery. Compound 9b might be an effective STAT3 inhibitor lead for the further development of antitumor agents.
Keywords: 2-Phenyl quinoline-4-carboxylic acid, Breast cancer cell lines, Quinoline, SH2 domian, Small molecule inhibitor, STAT3
Letters in Drug Design & Discovery
Title:Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3
Volume: 10 Issue: 5
Author(s): Zhi-Bing Shi, Lei Zhang, Zheng-Yang Bin, Xiang-Rong Cao, Zhu-Nan Gong and Jian-Xin Li
Affiliation:
Keywords: 2-Phenyl quinoline-4-carboxylic acid, Breast cancer cell lines, Quinoline, SH2 domian, Small molecule inhibitor, STAT3
Abstract: As STAT3 has been validated as an anticancer target, its inhibitors have been shown to possess therapeutic promise for the treatment of human cancers. To identify novel and selective STAT3 inhibitors, a virtual screening based on the STAT3 SH2 domain was performed and a small molecule, 2-phenylquinoline-4-carboxylic acid (5a), with an inhibition constant Ki value of 17.53 μM to STAT3 was discovered. On this basis, the derivatives of 5a including esters, amides and dimers were synthesized. The bioactivity and inhibitory selectivity of the derivatives were assayed using human breast cancer cell lines, MDA-MB-468 and MCF-7. Among the derivatives, 5c and 9b showed the most potent inhibitory activity with a good selectivity, and also inhibited STAT3 protein level of MDA-MB-468 cells. The results demonstrated a successful application of virtual screening for lead discovery. Compound 9b might be an effective STAT3 inhibitor lead for the further development of antitumor agents.
Export Options
About this article
Cite this article as:
Shi Zhi-Bing, Zhang Lei, Bin Zheng-Yang, Cao Xiang-Rong, Gong Zhu-Nan and Li Jian-Xin, Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3, Letters in Drug Design & Discovery 2013; 10 (5) . https://dx.doi.org/10.2174/1570180811310050009
DOI https://dx.doi.org/10.2174/1570180811310050009 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Current Drug Abuse Reviews Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Intracellular Trafficking Mechanism and Cytosolic Protein Interactions of a Non Viral Gene Delivery Vector: Studies Based on Transferrin Conjugated Pullulan-PEI
Current Nanoscience Thyroid Hormones Crosstalk with Growth Factors: Old Facts and New Hypotheses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) SALL4: Engine of Cell Stemness
Current Gene Therapy Subject Index to Volume 4
Current Medicinal Chemistry - Anti-Cancer Agents Senescence and Cell Death Pathways and Their Role in Cancer Therapeutic Outcome
Current Medicinal Chemistry Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice
Current Cancer Drug Targets Adult Neural Stem Cell Therapy: Expansion In Vitro, Tracking In Vivo and Clinical Transplantation
Current Drug Targets Use of the Bradykinin Agonist, Cereport as a Pharmacological Means of Increasing Drug Delivery to the CNS
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Cardiovascular Drug Development Using Radiopharmaceuticals
Current Pharmaceutical Design Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design Cell Responses to Oxidative Stressors
Current Pharmaceutical Design Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Cell Metabolism Under Microenvironmental Low Oxygen Tension Levels in Stemness, Proliferation and Pluripotency
Current Molecular Medicine Tyrosine Kinase Update: Role and Response in Cancer Therapy
Current Cancer Therapy Reviews Physiological Functions of Presenilins; Beyond γ-Secretase
Current Pharmaceutical Biotechnology The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets